[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574640":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":45,"centralContacts":46,"locations":45,"responsibleParty":52,"collaborators":45,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":45,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":45,"enrollmentInfo":65,"targetDuration":45,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":80,"whyStopped":45,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":45},{"fullName":5,"class":6},"Dalian Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"BV monotherapy group","ACTIVE_COMPARATOR","It was initially planned that BV monotherapy would be divided into two groups: a 2-week (2W) dosing group and a 3-week (3W) dosing group. The specific dosing method was determined by the investigator, but the duration of dosing could not exceed 1 year.",[13],"Drug: Brentuximab Vedotin (Bv)",{"label":15,"type":10,"description":16,"interventionNames":17},"BV combined treatment group","For the combined treatment group, it is recommended to use drugs with low neurotoxicity, such as bendamustine and gemcitabine, and dacarbazine and etoposide can also be selected. Anti-pd-1 monoclonal antibody is recommended to be administered once every 3 weeks, and sintilimab or somatorellimab can be selected. Patients who had failed previous treatment with anti-PD-1 anti-PD-1 monoclonal antibody could also be enrolled, at the discretion of the investigator.",[13,18,19,20],"Drug: Sintilimab","Drug: Tislelizumab","Drug: Bendamustine",[22,30,36,41],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Brentuximab Vedotin (Bv)","1.2mg\u002Fkg\u002F2w or 1.8mg\u002Fkg\u002F3w",[15,9],[28,29],"BV","Adcetris",{"type":23,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Sintilimab","200mg\u002F3w",[15],[35],"TYVYT",{"type":23,"name":37,"description":32,"armGroupLabels":38,"otherNames":39},"Tislelizumab",[15],[40],"TEVIMBRA",{"type":23,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Bendamustine","90mg\u002Fm2\u002F3w",[15],null,[47],{"name":48,"role":49,"phone":50,"phoneExt":45,"email":51},"XIUHUA SUN","CONTACT","86-0411-84671291","3038668@vip.sina.com",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":45,"oldOrganization":45},"SPONSOR_INVESTIGATOR","Xiuhua Sun","Head of Lymphoma and Head and Neck Oncology","100574640","phase-4-bv-in-the-treatment-of-relapsedrefractory-hodgkin-lymphoma-100574640",false,"NCT06761911","BV in the Treatment of Relapsed\u002Frefractory Hodgkin Lymphoma","A Real-world Study of Brentuximab Vedotin Monotherapy and Combination Regimens in the Treatment of Relapsed\u002FRefractory Hodgkin Lymphoma","Inclusion Criteria:\n\n* Histologically, classical hodgkin lymphoma（cHL） was diagnosed and relapsed or refractory.\n* Patients were treated with BV-containing regimen at least once\n* Presence of tumor (measurable or nonmeasurable).\n* Signature of the form consent for participation in the study.\n\nExclusion Criteria:\n\n* \\\u003C18 years","ALL","18 Years",{"count":66,"type":67},100,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","The goal of this clinical trial is to explore the real-world Chinese relapsed\u002Frefractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are:\n\nTo evaluate the efficacy and toxicity of BV-containing regimen in relapsed\u002Frefractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.",[73],"Hodgkin Lymphoma (Category)",[75,76,77,78,79],"Brentuximab Vedotin","Hodgkin lymphoma","refractory recurrence","real world","china","NOT_YET_RECRUITING","2025-01-06",{"date":83,"type":84},"2025-01-07","ACTUAL",{"date":86,"type":67},"2024-12-31",{"date":88,"type":67},"2026-01-31",{"name":54,"class":6}]